Trinity Biotech Statistics
Total Valuation
Trinity Biotech has a market cap or net worth of $13.62 million. The enterprise value is $124.64 million.
Important Dates
The next estimated earnings date is Saturday, February 14, 2026, after market close.
| Earnings Date | Feb 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Trinity Biotech has 18.57 million shares outstanding. The number of shares has increased by 168.60% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 18.57M |
| Shares Change (YoY) | +168.60% |
| Shares Change (QoQ) | +0.91% |
| Owned by Insiders (%) | 3.05% |
| Owned by Institutions (%) | 4.93% |
| Float | 13.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.34 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.05
| Current Ratio | 1.05 |
| Quick Ratio | 0.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.78% |
| Return on Invested Capital (ROIC) | -16.47% |
| Return on Capital Employed (ROCE) | -24.56% |
| Revenue Per Employee | $123,214 |
| Profits Per Employee | -$90,970 |
| Employee Count | 401 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.52 |
Taxes
In the past 12 months, Trinity Biotech has paid $850,000 in taxes.
| Income Tax | 850,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.57% in the last 52 weeks. The beta is 0.56, so Trinity Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -14.57% |
| 50-Day Moving Average | 0.93 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 38.64 |
| Average Volume (20 Days) | 9,383,473 |
Short Selling Information
| Short Interest | 23,097 |
| Short Previous Month | 50,471 |
| Short % of Shares Out | 0.67% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.61 |
Income Statement
In the last 12 months, Trinity Biotech had revenue of $49.41 million and -$36.48 million in losses. Loss per share was -$1.70.
| Revenue | 49.41M |
| Gross Profit | 16.71M |
| Operating Income | -16.73M |
| Pretax Income | -35.06M |
| Net Income | -36.48M |
| EBITDA | -15.60M |
| EBIT | -16.73M |
| Loss Per Share | -$1.70 |
Full Income StatementBalance Sheet
The company has $1.55 million in cash and $112.56 million in debt, with a net cash position of -$111.01 million or -$5.98 per share.
| Cash & Cash Equivalents | 1.55M |
| Total Debt | 112.56M |
| Net Cash | -111.01M |
| Net Cash Per Share | -$5.98 |
| Equity (Book Value) | -49.54M |
| Book Value Per Share | -2.66 |
| Working Capital | 1.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.86 million and capital expenditures -$360,000, giving a free cash flow of -$5.22 million.
| Operating Cash Flow | -4.86M |
| Capital Expenditures | -360,000 |
| Free Cash Flow | -5.22M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
Gross margin is 33.81%, with operating and profit margins of -33.86% and -73.83%.
| Gross Margin | 33.81% |
| Operating Margin | -33.86% |
| Pretax Margin | -70.95% |
| Profit Margin | -73.83% |
| EBITDA Margin | -31.58% |
| EBIT Margin | -33.86% |
| FCF Margin | n/a |
Dividends & Yields
Trinity Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -168.60% |
| Shareholder Yield | -168.60% |
| Earnings Yield | -267.76% |
| FCF Yield | -38.34% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 23, 2024. It was a reverse split with a ratio of 1:5.
| Last Split Date | Feb 23, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
Trinity Biotech has an Altman Z-Score of -1.29 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.29 |
| Piotroski F-Score | 1 |
